23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Keros Therapeutics, Inc. › 2025-2026

Keros Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Keros Therapeutics, Inc.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 180Asset managers, any item
  • 848Fund votes
  • June 3, 2026Meeting date

Results at a glance

Meeting of June 3, 2026: 4 items on Keros Therapeutics, Inc.’s Form 8-K, filed June 3, 2026: 2 elected · 2 approved.

Dissent

Significant dissent: 1 director (33.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Nantahala Capital (13F, 7.6%, as of September 30, 2026)

Explore Keros Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Keros Therapeutics, Inc.

These tallies are Keros Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Keros Therapeutics, Inc. — official shareholder meeting results, meeting held June 3, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jean-Jacques Bienaimé 10,093,559---- 5,156,1532,243,514 66%Elected—
Elect Director: Charles Newton 14,716,598---- 533,1142,243,514 97%Elected—
2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 16,708,279783,953994 ---- 96%Approved—
3. Advisory Vote on Executive Compensation 14,273,625974,0492,038 --2,243,514 94%Approved—

Source: Keros Therapeutics, Inc., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.

How asset managers voted at the Keros Therapeutics, Inc. 2025-2026 meeting

180 asset managers disclosed a vote on at least one Keros Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Charles Newton

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 14,716,598WITHHELD: 533,114
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders: Charles Newton

Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles Newton”): 14,716,598 for, 533,114 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the two persons listed below as directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 5,780,807 for, 14,730 withheld, 1 abstained.

FOR
FOR: 5,780,807ABSTAIN: 1WITHHOLD: 14,730
Largest asset managers voting on “To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting ” at Keros Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,475,9430 10For
BlackRock1,116,0620 00For
Fidelity614,7830 00For
Federated Hermes514,4000 00For
TIAA260,3850 00For
Charles Schwab179,9910 00For
Bridge Builder Trust162,2940 00For
EA Series Trust145,5170 00For
OLD WESTBURY FUNDS INC143,8530 00For
Dimensional123,8080 00For
Columbia Threadneedle98,7540 00For
Nationwide90,9750 00For
SEI73,4920 00For
American Century66,3590 00For
Equitable62,7650 00For
Invesco61,7930 00For
Principal Exchange-Traded Funds58,8990 00For
BRIDGEWAY FUNDS INC49,5000 00For
GuideStone49,2970 00For
QUANTITATIVE MASTER SERIES LLC47,5840 00For
Goldman Sachs42,2180 00For
MFS40,8600 00For
SEI Exchange Traded Funds35,7470 00For
AQR34,5820 00For
WisdomTree31,1760 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Elect Director: Jean-Jacques Bienaimé

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%WITHHELD
FOR: 10,093,559WITHHELD: 5,156,153
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders: Jean-Jacques Bienaime

Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Jean-Jacques Bienaimé”): 10,093,559 for, 5,156,153 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the two persons listed below as directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 4,630,028 for, 1,165,499 withheld, 11 abstained.

FORWITHHOLD
FOR: 4,630,028ABSTAIN: 11WITHHOLD: 1,165,499
Largest asset managers voting on “To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting ” at Keros Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,475,2340 11699For
BlackRock1,116,0620 00For
Fidelity614,7830 00For
Federated Hermes514,4000 00For
TIAA260,3850 00For
Charles Schwab179,9910 00For
Bridge Builder Trust162,2940 00For
EA Series Trust00 0145,517Withhold
OLD WESTBURY FUNDS INC00 0143,853Withhold
Dimensional00 0123,808Withhold
Columbia Threadneedle98,7540 00For
Nationwide9,7480 081,227Mixed
SEI00 073,492Withhold
American Century00 066,359Withhold
Equitable43,1650 019,600Mixed
Invesco61,7930 00For
Principal Exchange-Traded Funds00 058,899Withhold
BRIDGEWAY FUNDS INC00 049,500Withhold
GuideStone00 049,297Withhold
QUANTITATIVE MASTER SERIES LLC47,5840 00For
Goldman Sachs00 042,218Withhold
MFS00 040,860Withhold
SEI Exchange Traded Funds00 035,747Withhold
AQR00 034,582Withhold
WisdomTree00 031,176Withhold

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 14,273,625AGAINST: 974,049

Prior year: 81.7% for (June 4, 2025 meeting) ▲ 11.9 pts

Details: description as filed, official tally, votes by 180 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.

Keros Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 14,273,625 for, 974,049 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 59 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN T” at Keros Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,475,9431 00For
BlackRock1,116,0620 00For
Fidelity614,7830 00For
Federated Hermes514,4000 00For
TIAA260,3850 00For
Charles Schwab179,9910 00For
Bridge Builder Trust162,2940 00For
EA Series Trust145,5170 00For
OLD WESTBURY FUNDS INC143,8530 00For
Dimensional123,8080 00For
Columbia Threadneedle98,7540 00For
Nationwide90,9750 00For
SEI73,4920 00For
American Century066,359 00Against
Equitable62,7650 00For
Invesco61,7930 00For
Principal Exchange-Traded Funds58,8990 00For
BRIDGEWAY FUNDS INC49,5000 00For
GuideStone49,2970 00For
QUANTITATIVE MASTER SERIES LLC47,5840 00For
Goldman Sachs42,2180 00For
MFS40,8600 00For
SEI Exchange Traded Funds35,7470 00For
AQR34,5820 00For
WisdomTree31,1760 00For

Fund voting reports, all 59 managers: 5,712,362 for, 83,120 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 138 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN T” at Keros Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Nantahala Capital Management, LLC1,326,9470 00For
BlackRock923,5490 00For
ORBIMED ADVISORS LLC759,1550 00For
Federated Hermes680,5160 00For
GEODE CAPITAL MANAGEMENT, LLC672,7600 00For
State Street524,7740 00For
Madison Avenue Partners, LP0452,277 00Against
DE Shaw439,0500 00For
JACOBS LEVY EQUITY MANAGEMENT, INC403,4430 00For
Two Sigma326,2140 00For
BESSEMER INVESTMENT MANAGEMENT LLC287,7060 00For
Nuveen262,3320 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP244,6380 00For
AQR237,5060 00For
Charles Schwab180,0240 00For
Citadel167,5460 00For
MACKENZIE FINANCIAL CORP152,4500 00For
Vanguard144,1410 00For
WELLS FARGO CLEARING SERVICES, LLC140,0000 00For
ACADIAN ASSET MANAGEMENT LLC123,2520 00For
Northern Trust119,3130 00For
SEI109,6660 00For
MELLON INVESTMENTS Corp104,6900 00For
Point7290,3820 00For
Invesco86,7140 00For

Institutional-manager reports, all 138 managers: 9,811,083 for, 580,936 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the…

Official resultAUDIT-RELATEDReported outcome: Approved

96% Approved · of votes cast

FOR 96%
FOR: 16,708,279AGAINST: 783,953

Prior year: 99.2% for (June 4, 2025 meeting) ▼ 3.7 pts

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Keros Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026”): 16,708,279 for, 783,953 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 The Company's stockholders approved Proposal 2.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 5,795,537 for, 1 against.

FOR
FOR: 5,795,537AGAINST: 1
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEP” at Keros Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard1,475,9431 00For
BlackRock1,116,0620 00For
Fidelity614,7830 00For
Federated Hermes514,4000 00For
TIAA260,3850 00For
Charles Schwab179,9910 00For
Bridge Builder Trust162,2940 00For
EA Series Trust145,5170 00For
OLD WESTBURY FUNDS INC143,8530 00For
Dimensional123,8080 00For
Columbia Threadneedle98,7540 00For
Nationwide90,9750 00For
SEI73,4920 00For
American Century66,3590 00For
Equitable62,7650 00For
Invesco61,7930 00For
Principal Exchange-Traded Funds58,8990 00For
BRIDGEWAY FUNDS INC49,5000 00For
GuideStone49,2970 00For
QUANTITATIVE MASTER SERIES LLC47,5840 00For
Goldman Sachs42,2180 00For
MFS40,8600 00For
SEI Exchange Traded Funds35,7470 00For
AQR34,5820 00For
WisdomTree31,1760 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Largest Keros Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,791,837 shares outstanding at the time of that meeting.

Fund voting reports: top Keros Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 7.46%
2BlackRock 5.64%
3Fidelity 3.11%
4Federated Hermes 2.60%
5TIAA 1.32%
6Charles Schwab 0.91%
7Bridge Builder Trust 0.82%
8EA Series Trust 0.74%
9OLD WESTBURY FUNDS INC 0.73%
10Dimensional 0.63%
Institutional-manager reports: top Keros Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS…”, 2025-2026
#Asset manager % of shares outstanding
1Nantahala Capital Management, LLC 6.70%
2BlackRock 4.67%
3ORBIMED ADVISORS LLC 3.84%
4Federated Hermes 3.44%
5GEODE CAPITAL MANAGEMENT, LLC 3.40%
6State Street 2.65%
7Madison Avenue Partners, LP 2.29%
8DE Shaw 2.22%
9JACOBS LEVY EQUITY MANAGEMENT, INC 2.04%
10Two Sigma 1.65%

Reported Keros Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Keros Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock2,411,793 12.19%Form 13F, quarter ended March 31, 2026
Jasbir Seehra, Ph.D.1,871,682 9.46%Proxy statement (DEF 14A), table as of March 31, 2026
Vanguard Group1,525,355 7.71%Form 13F, quarter ended March 31, 2026
Nantahala Capital Management, LLC1,360,419 6.87%Schedule 13G, filed May 15, 2026
Madison Avenue International LP823,707 4.16%Schedule 13G, filed February 17, 2026
Geode Capital681,460 3.44%Form 13F, quarter ended March 31, 2026
State Street561,730 2.84%Form 13F, quarter ended March 31, 2026
Citadel Advisors553,766 2.80%Form 13F, quarter ended March 31, 2026
D.E. Shaw509,608 2.57%Form 13F, quarter ended March 31, 2026
Renaissance Technologies453,482 2.29%Form 13F, quarter ended March 31, 2026

Percentages above are of 19,791,837 shares outstanding, as reported by Keros Therapeutics, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Keros Therapeutics, Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 180 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 848 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS… — Keros Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Keros Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Keros Therapeutics, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Keros Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Keros Therapeutics (KROS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/keros-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.